Hans-Willi Krell

USPTO Granted Patents = 26 (Patent Applications = 6)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 4.8

ph-index = 6

Forward Citations = 120(Granted Patents)

Location History:

Monza, IT (2000)
Penzberg, DE (1997 - 2019)

Company Filing History:

12 out of 4,945

Hoffmann-la Roche Inc.

patents

5 out of 480

Roche Diagnostics Gmbh

patents

4 out of 1,164

Boehringer Mannheim Gmbh

F. Hoffmann-la Roche Ag

Years Active: 1997-2019

Loading Chart...

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10196456 - Anti-HER3 antibodies and uses thereof (2019-02-05),

2. 9611331 - Anti-HER3 antibodies and uses thereof (2017-04-04),

3. 9399670 - Method for obtaining immunoglobulin encoding nucleic acid (2016-07-26),

4. 9290567 - Use of an anti-Tau pS422 antibody for the treatment of brain diseases (2016-03-22),

5. 8883159 - Antibodies against CDCP1 for the treatment of cancer (2014-11-11),

6. 8859737 - Anti-HER3 antibodies and uses thereof (2014-10-14),

7. 8609097 - Use of an anti-Tau pS422 antibody for the treatment of brain diseases (2013-12-17),

8. 8207307 - Antibodies against human CCN1 and uses thereof (2012-06-26),

9. 8044035 - Pharmaceutical compositions of pyrimidine-2,4,6-triones (2011-10-25),

10. 7429605 - Phenylpyridine derivatives (2008-09-30),

11. 7285569 - Tricycles, their manufacture and use as pharmaceutical agents (2007-10-23),

12. 6946471 - 2-(2,6-Dichlorophenyl)-Diarylimidazoles (2005-09-20),

13. 6790852 - 2-(2,6-dichlorophenyl)-diarylimidazoles (2004-09-14),

14. 6716845 - Barbituric acid derivatives (2004-04-06),

15. 6576628 - 3-aryl-succinamido-hydroxamic acids, methods for producing said acids and medicaments containing the same (2003-06-10),

Title: The Innovative Contributions of Hans-Willi Krell

Introduction: Hans-Willi Krell is a distinguished inventor based in Penzberg, Germany. He has made significant strides in the field of biotechnology, with an impressive portfolio of 26 patents. His work primarily focuses on the development of antibodies for therapeutic use, showcasing his innovative spirit and commitment to advancing medical science.

Latest Patents: Among his notable inventions are the patents for anti-HER3 antibodies and their uses. These inventions relate to antibodies that specifically bind to human HER3, detailing methods for their production, pharmaceutical compositions that incorporate these antibodies, and their potential therapeutic applications. This groundbreaking work has the potential to impact the treatment of various diseases significantly.

Career Highlights: Krell's career has included pivotal roles at prominent companies such as Hoffmann-La Roche Inc. and Roche Diagnostics GmbH. His contributions in these organizations not only demonstrate his expertise in biotechnology but also affirm his reputation as a leading figure in the field.

Collaborations: Throughout his career, Krell has collaborated with eminent professionals, including Ernesto Menta and Valeria Lifke. These partnerships have enriched his research and expanded the reach of his innovations, allowing for a collaborative approach to tackling complex scientific challenges.

Conclusion: Hans-Willi Krell's impressive body of work and his numerous patents underscore his role as an innovative force in biotechnology. His contributions, particularly in the development of anti-HER3 antibodies, highlight the importance of collaboration and creativity in advancing healthcare solutions. His ongoing commitment to research and development continues to inspire future inventions in the field.

This text is generated by artificial intelligence and may not be accurate.